Amyloid-β and mitochondria in aging and Alzheimer's disease

Implications for synaptic damage and cognitive decline

P (Hemachandra) Reddy, Maria Manczak, Peizhong Mao, Marcus J. Calkins, Arubala Reddy, Ulziibat Shirendeb

    Research output: Contribution to journalArticle

    144 Citations (Scopus)

    Abstract

    This article reviews the role of amyloid-β (Aβ) and mitochondria in synaptic damage and cognitive decline found in patients with Alzheimer's disease (AD). Recent molecular, cellular, animal model, and postmortem brain studies have revealed that Aβ and mitochondrial abnormalities are key factors that cause synaptic damage and cognitive decline in AD. Aβ is reported to accumulate in subcellular compartments and to impair the normal function of neurons in AD patients. Further, recent studies using biochemical methods and electron microscopy have revealed that the accumulation of Aβ at nerve terminals affect synaptic activities, including the release of neurotransmitters and synaptic vesicles. Recent studies of the relationship between mitochondria and Aβ in AD patients suggest that in mitochondria, structural changes caused by Aβ result in increased mitochondrial fragmentation, decreased mitochondrial fusion, mitochondrial dysfunction, and synaptic damage. This paper discusses the latest research on Aβ, mitochondria, age-dependent factors of AD in the brain, and synaptic damage in AD. This paper also briefly discusses potential mitochondrial therapeutics in the treatment of patients with AD.

    Original languageEnglish (US)
    JournalJournal of Alzheimer's Disease
    Volume20
    Issue numberSUPPL.2
    DOIs
    StatePublished - 2010

    Fingerprint

    Amyloid
    Alzheimer Disease
    Mitochondria
    Mitochondrial Dynamics
    Synaptic Vesicles
    Age Factors
    Presynaptic Terminals
    Brain
    Cognitive Dysfunction
    Neurotransmitter Agents
    Electron Microscopy
    Animal Models
    Neurons
    Therapeutics
    Research

    Keywords

    • Amyloid-β
    • amyloid-β precursor protein
    • mitochondrial therapeutics
    • synaptic pathology

    ASJC Scopus subject areas

    • Psychiatry and Mental health
    • Geriatrics and Gerontology
    • Clinical Psychology

    Cite this

    Amyloid-β and mitochondria in aging and Alzheimer's disease : Implications for synaptic damage and cognitive decline. / Reddy, P (Hemachandra); Manczak, Maria; Mao, Peizhong; Calkins, Marcus J.; Reddy, Arubala; Shirendeb, Ulziibat.

    In: Journal of Alzheimer's Disease, Vol. 20, No. SUPPL.2, 2010.

    Research output: Contribution to journalArticle

    Reddy, P (Hemachandra) ; Manczak, Maria ; Mao, Peizhong ; Calkins, Marcus J. ; Reddy, Arubala ; Shirendeb, Ulziibat. / Amyloid-β and mitochondria in aging and Alzheimer's disease : Implications for synaptic damage and cognitive decline. In: Journal of Alzheimer's Disease. 2010 ; Vol. 20, No. SUPPL.2.
    @article{5d4345656182413fa23658ff6a2b3fe4,
    title = "Amyloid-β and mitochondria in aging and Alzheimer's disease: Implications for synaptic damage and cognitive decline",
    abstract = "This article reviews the role of amyloid-β (Aβ) and mitochondria in synaptic damage and cognitive decline found in patients with Alzheimer's disease (AD). Recent molecular, cellular, animal model, and postmortem brain studies have revealed that Aβ and mitochondrial abnormalities are key factors that cause synaptic damage and cognitive decline in AD. Aβ is reported to accumulate in subcellular compartments and to impair the normal function of neurons in AD patients. Further, recent studies using biochemical methods and electron microscopy have revealed that the accumulation of Aβ at nerve terminals affect synaptic activities, including the release of neurotransmitters and synaptic vesicles. Recent studies of the relationship between mitochondria and Aβ in AD patients suggest that in mitochondria, structural changes caused by Aβ result in increased mitochondrial fragmentation, decreased mitochondrial fusion, mitochondrial dysfunction, and synaptic damage. This paper discusses the latest research on Aβ, mitochondria, age-dependent factors of AD in the brain, and synaptic damage in AD. This paper also briefly discusses potential mitochondrial therapeutics in the treatment of patients with AD.",
    keywords = "Amyloid-β, amyloid-β precursor protein, mitochondrial therapeutics, synaptic pathology",
    author = "Reddy, {P (Hemachandra)} and Maria Manczak and Peizhong Mao and Calkins, {Marcus J.} and Arubala Reddy and Ulziibat Shirendeb",
    year = "2010",
    doi = "10.3233/JAD-2010-100504",
    language = "English (US)",
    volume = "20",
    journal = "Journal of Alzheimer's Disease",
    issn = "1387-2877",
    publisher = "IOS Press",
    number = "SUPPL.2",

    }

    TY - JOUR

    T1 - Amyloid-β and mitochondria in aging and Alzheimer's disease

    T2 - Implications for synaptic damage and cognitive decline

    AU - Reddy, P (Hemachandra)

    AU - Manczak, Maria

    AU - Mao, Peizhong

    AU - Calkins, Marcus J.

    AU - Reddy, Arubala

    AU - Shirendeb, Ulziibat

    PY - 2010

    Y1 - 2010

    N2 - This article reviews the role of amyloid-β (Aβ) and mitochondria in synaptic damage and cognitive decline found in patients with Alzheimer's disease (AD). Recent molecular, cellular, animal model, and postmortem brain studies have revealed that Aβ and mitochondrial abnormalities are key factors that cause synaptic damage and cognitive decline in AD. Aβ is reported to accumulate in subcellular compartments and to impair the normal function of neurons in AD patients. Further, recent studies using biochemical methods and electron microscopy have revealed that the accumulation of Aβ at nerve terminals affect synaptic activities, including the release of neurotransmitters and synaptic vesicles. Recent studies of the relationship between mitochondria and Aβ in AD patients suggest that in mitochondria, structural changes caused by Aβ result in increased mitochondrial fragmentation, decreased mitochondrial fusion, mitochondrial dysfunction, and synaptic damage. This paper discusses the latest research on Aβ, mitochondria, age-dependent factors of AD in the brain, and synaptic damage in AD. This paper also briefly discusses potential mitochondrial therapeutics in the treatment of patients with AD.

    AB - This article reviews the role of amyloid-β (Aβ) and mitochondria in synaptic damage and cognitive decline found in patients with Alzheimer's disease (AD). Recent molecular, cellular, animal model, and postmortem brain studies have revealed that Aβ and mitochondrial abnormalities are key factors that cause synaptic damage and cognitive decline in AD. Aβ is reported to accumulate in subcellular compartments and to impair the normal function of neurons in AD patients. Further, recent studies using biochemical methods and electron microscopy have revealed that the accumulation of Aβ at nerve terminals affect synaptic activities, including the release of neurotransmitters and synaptic vesicles. Recent studies of the relationship between mitochondria and Aβ in AD patients suggest that in mitochondria, structural changes caused by Aβ result in increased mitochondrial fragmentation, decreased mitochondrial fusion, mitochondrial dysfunction, and synaptic damage. This paper discusses the latest research on Aβ, mitochondria, age-dependent factors of AD in the brain, and synaptic damage in AD. This paper also briefly discusses potential mitochondrial therapeutics in the treatment of patients with AD.

    KW - Amyloid-β

    KW - amyloid-β precursor protein

    KW - mitochondrial therapeutics

    KW - synaptic pathology

    UR - http://www.scopus.com/inward/record.url?scp=77956199725&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=77956199725&partnerID=8YFLogxK

    U2 - 10.3233/JAD-2010-100504

    DO - 10.3233/JAD-2010-100504

    M3 - Article

    VL - 20

    JO - Journal of Alzheimer's Disease

    JF - Journal of Alzheimer's Disease

    SN - 1387-2877

    IS - SUPPL.2

    ER -